COMP <GO>
KYMR vs NBIX // 10Y YIELD & FRED MACRO BETA
Kymera Therapeutics Inc. (NASDAQ) VS. Neurocrine Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: KYMR 3
— NBIX 8
▲ 10Y YIELD & FRED MACRO BETA LEADER: NBIX
LAST: $127.51 (+0.70%) • MKT CAP: $10.81B
macro-sensitivity
0.95
LAST: $145.35 (-0.51%) • MKT CAP: $14.85B
macro-sensitivity
1.13
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. NBIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | NBIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 15.70% | -37.10 | NBIX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 22.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 5.03% | -7.33 | NBIX | /fcf-yield <GO> |
| Operating Margin | -60.00% | 21.60% | -81.60 | NBIX | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 16.70% | +51.30 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 21.40% | -38.10 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 8.13 | +17.87 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 55.2 | +10.80 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 1.13 | -0.18 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 26.1x | +4.30 | NBIX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.81B | $14.85B | -$4.04B | NBIX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | NBIX REV | KYMR GROSS % | NBIX GROSS % | KYMR FCF | NBIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $2.86B | 0.0% | 98.2% | -$234.3M | $748.7M |
| FY 2024 | $47.1M | $2.36B | 0.0% | 98.6% | -$207.3M | $557.2M |
| FY 2023 | $78.6M | $1.89B | — | — | -$106.4M | $305.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
NBIX // BETA 1.13